NO20082496L - Pyrazinderivater - Google Patents

Pyrazinderivater

Info

Publication number
NO20082496L
NO20082496L NO20082496A NO20082496A NO20082496L NO 20082496 L NO20082496 L NO 20082496L NO 20082496 A NO20082496 A NO 20082496A NO 20082496 A NO20082496 A NO 20082496A NO 20082496 L NO20082496 L NO 20082496L
Authority
NO
Norway
Prior art keywords
compounds
pyrazine derivatives
preparation
solvates
pain
Prior art date
Application number
NO20082496A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen Martin Denton
Mark Ian Kemp
Karl Richard Gibson
Cedric Poinsard
Melanie Susanne Glossop
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NO20082496L publication Critical patent/NO20082496L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20082496A 2005-11-04 2008-06-04 Pyrazinderivater NO20082496L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73366205P 2005-11-04 2005-11-04
PCT/IB2006/003055 WO2007052123A2 (en) 2005-11-04 2006-10-23 Pyrazine derivatives as sodium channel modulators for the treatment of pain

Publications (1)

Publication Number Publication Date
NO20082496L true NO20082496L (no) 2008-07-24

Family

ID=37890558

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082496A NO20082496L (no) 2005-11-04 2008-06-04 Pyrazinderivater

Country Status (27)

Country Link
US (1) US7572797B2 (de)
EP (1) EP1945630B1 (de)
JP (1) JP2009514937A (de)
KR (1) KR20080066073A (de)
CN (1) CN101356169A (de)
AP (1) AP2008004468A0 (de)
AR (1) AR057855A1 (de)
AT (1) ATE525372T1 (de)
AU (1) AU2006310215A1 (de)
BR (1) BRPI0618129A2 (de)
CA (1) CA2624621C (de)
CR (1) CR9954A (de)
DO (1) DOP2006000243A (de)
EA (1) EA200801011A1 (de)
EC (1) ECSP088412A (de)
ES (1) ES2371932T3 (de)
GT (1) GT200600475A (de)
IL (1) IL191059A0 (de)
MA (1) MA29926B1 (de)
NL (1) NL2000284C2 (de)
NO (1) NO20082496L (de)
PE (1) PE20070715A1 (de)
TN (1) TNSN08196A1 (de)
TW (1) TW200804353A (de)
UY (1) UY29893A1 (de)
WO (1) WO2007052123A2 (de)
ZA (1) ZA200803671B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (de) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba und dessen derivate zur schmerzbehandlung
EP1741708A1 (de) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit ungesättigtem oder zyklischem Linker, und deren Verwendung als Pharmaka
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US20100227872A1 (en) * 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
WO2009026434A1 (en) * 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
JPWO2009101917A1 (ja) 2008-02-13 2011-06-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 ビシクロアミン誘導体
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) * 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
ES2645984T3 (es) * 2012-04-25 2017-12-11 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de TTX-S
EP3495359A1 (de) 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap-modulatoren
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
CA2960274A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
TWI771269B (zh) 2015-02-27 2022-07-21 美商鈣系醫藥公司 胰腺炎治療
CA2995094A1 (en) * 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
CA3172249A1 (en) 2020-03-20 2021-09-23 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
JP7791898B2 (ja) 2020-11-13 2025-12-24 カルシメディカ，インク． Ｃｒａｃチャネル阻害剤の合成の改善

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA26473A1 (fr) * 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
DE60234269D1 (de) * 2001-11-21 2009-12-17 Pharmacia & Upjohn Co Llc Substituierte aryl 1,4-pyrazin derivate
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CA2543644A1 (en) * 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
CN101084208A (zh) * 2004-10-22 2007-12-05 詹森药业有限公司 作为c－fms激酶抑制剂的芳族酰胺

Also Published As

Publication number Publication date
ZA200803671B (en) 2009-03-25
TW200804353A (en) 2008-01-16
MA29926B1 (fr) 2008-11-03
PE20070715A1 (es) 2007-08-11
CR9954A (es) 2008-05-28
EA200801011A1 (ru) 2009-02-27
ATE525372T1 (de) 2011-10-15
CA2624621C (en) 2010-11-30
WO2007052123A2 (en) 2007-05-10
DOP2006000243A (es) 2007-05-31
EP1945630A2 (de) 2008-07-23
GT200600475A (es) 2007-07-06
US20070105872A1 (en) 2007-05-10
BRPI0618129A2 (pt) 2011-08-16
TNSN08196A1 (fr) 2009-10-30
NL2000284A1 (nl) 2007-05-07
EP1945630B1 (de) 2011-09-21
JP2009514937A (ja) 2009-04-09
ECSP088412A (es) 2008-05-30
AU2006310215A1 (en) 2007-05-10
UY29893A1 (es) 2007-06-29
ES2371932T3 (es) 2012-01-11
CA2624621A1 (en) 2007-05-10
IL191059A0 (en) 2008-12-29
KR20080066073A (ko) 2008-07-15
AR057855A1 (es) 2007-12-19
US7572797B2 (en) 2009-08-11
CN101356169A (zh) 2009-01-28
WO2007052123A3 (en) 2007-07-12
AP2008004468A0 (en) 2008-06-30
NL2000284C2 (nl) 2007-09-28

Similar Documents

Publication Publication Date Title
WO2006011050A3 (en) Pyridine derivatives
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
MX2009011816A (es) Derivados de piridina.
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
TW200833675A (en) Nicotinamide derivatives
MX2011007424A (es) Derivados de sulfonamida.
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20081844L (no) Terapeutiske forbindelser
NO20050828L (no) lndol-3-svovelderivater
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2007052123A3 (en) Pyrazine derivatives as sodium channel modulators for the treatment of pain
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20074703L (no) Antibakterielle piperidinderivater
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MXPA05012247A (es) Derivados de bencimidazol nuevos.
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
UA96277C2 (en) Benzimidazole derivatives
TW200716529A (en) New compounds II

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application